Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).

As the cycles were delivered, a clear trend toward an increase in lymphopoenia was observed, being present in 30% of patients during the first three cycles, and in 55% of the patients in the subsequent cycles.

also in 19,460 other papers